NCPC(SH:600812)2021-04-28 16:00Financial Performance - The company reported a net profit attributable to shareholders of the listed company for 2020 was ¥97,323,761.87, a decrease of 43.46% from ¥172,147,389.25 in 2019[27]. - The company's operating revenue for 2020 was ¥11,492,504,163.48, representing a year-on-year increase of 0.31% compared to ¥11,457,480,504.85 in 2019[27]. - Total profit for the year was CNY 1.87 billion, representing a decrease of 28.38% compared to the previous year[62]. - The total assets at the end of 2020 amounted to ¥23,931,716,749.91, reflecting a significant increase of 26.55% from ¥18,910,689,810.40 in 2019[27]. - The gross profit margin decreased by 4.80 percentage points to 36.27% compared to the previous year[72]. - The revenue from the anti-infection category was approximately ¥5.51 billion, showing a year-on-year decrease of 15.55%[140]. - The company reported a significant increase in revenue, achieving a total of $X million for the fiscal year, representing a Y% growth compared to the previous year[122]. Dividends and Profit Distribution - The company plans to distribute a cash dividend of RMB 0.30 per 10 shares, totaling approximately RMB 48.92 million, which represents 50.27% of the net profit attributable to shareholders for the year[6]. - The company has a total distributable profit of RMB 736,781,117.17 as of December 31, 2020, after accounting for previous distributions and reserves[199]. - The company has established a shareholder return plan, committing to distribute at least 30% of the average distributable profit over the last three years as cash dividends[199]. - The company’s cash dividend for 2019 was also RMB 0.30 per 10 shares, amounting to RMB 48,924,141.87, which was 31.88% of the net profit for that year[200]. Internal Controls and Audit - The company has identified one significant internal control deficiency in its internal control evaluation report for 2020[11]. - The company has received a standard unqualified audit opinion from Zhongtian Yun Accounting Firm for the 2020 financial statements[5]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[8]. - The company has not violated decision-making procedures in providing guarantees[8]. Market and Industry Trends - The pharmaceutical manufacturing industry is expected to grow steadily due to increasing demand driven by population aging and urbanization in China[94]. - The biopharmaceutical sector is experiencing rapid growth, with a focus on innovative drugs for cancer and infectious diseases, indicating a promising future[97]. - The health and nutrition sector is anticipated to grow over 10% annually, driven by increasing health awareness and supportive policies in China[103]. - The trend of centralized drug procurement is becoming normalized, with an expansion in the range of drugs included, effectively lowering drug prices[188]. Research and Development - The company applied for 37 invention patents and was granted 41 invention patents during the year[62]. - Research and development expenses increased by 60.64% year-on-year, amounting to CNY 136.16 million[64]. - The company’s R&D investment amounted to 469 million RMB, accounting for 4.08% of operating revenue, which is in line with the industry average[162]. - The major R&D projects include the development of recombinant antibodies and new drugs, with significant investments such as 55.9 million RMB for rabies virus antibodies and 22.1 million RMB for recombinant human vascular endothelial growth factor monoclonal antibody[166]. Product Development and Sales - The company has a comprehensive product line in the pharmaceutical manufacturing industry, covering over 700 product specifications, including antibiotics and cardiovascular drugs[37]. - The company is focusing on the development of high-value-added projects, particularly in biopharmaceuticals and oncology treatments[37]. - The company’s new product pipeline includes innovative therapies for various diseases, enhancing its market position[132]. - The company is actively pursuing market expansion and innovation in drug development, with a focus on high-demand therapeutic areas[144]. Risk Management - The company emphasizes the importance of risk awareness regarding forward-looking statements due to inherent uncertainties[7]. - The company faces risks from a complex pharmaceutical operating environment, including slowing growth in total pharmaceutical output and rising costs due to regulatory changes[196]. - The company emphasizes the importance of risk prevention and control in key areas such as finance, safety, quality, and environmental protection[195]. Acquisitions and Investments - The company completed the acquisition of 51% of Aino Company and 100% of Dongbao Company, with a total transaction value of 885.71 million yuan[52]. - The acquisition of 51% equity in Ainor Company was valued at 151.61 million RMB, while the acquisition of 100% equity in Dongbao Company was valued at 74.50 million RMB[177]. - The total investment in new projects reached 613,795,523.85 RMB, with significant contributions from self-raised funds and loans[178]. Future Outlook - Future outlook remains positive, with management expressing confidence in achieving long-term growth objectives[123]. - The company aims to achieve a revenue of 12.5 billion yuan and a total profit of 300 million yuan in 2021[191]. - The company plans to enhance its drug research and development capabilities and aims to become a leading domestic drug R&D center[190].